|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:accreditation
|
gptkb:FDA
gptkb:WHO
gptkb:EMA
|
|
gptkbp:acquisition
|
gptkb:Sinopharm_Group
|
|
gptkbp:awards
|
Innovation Award 2021
Excellence in Research 2019
Best Pharmaceutical Company 2020
|
|
gptkbp:ceo
|
Liang Zhiqiang
|
|
gptkbp:clinical_trial
|
multiple ongoing
|
|
gptkbp:collaboration
|
international research institutions
|
|
gptkbp:community_engagement
|
disaster relief efforts
health education programs
public health campaigns
|
|
gptkbp:distribution_channels
|
global
|
|
gptkbp:employees
|
over 30,000
|
|
gptkbp:founded
|
gptkb:1992
|
|
gptkbp:future_plans
|
enter new markets
increase R& D investment
expand vaccine production
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:headquarters
|
gptkb:Beijing,_China
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sino-Pharm
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:investment
|
biotech startups
|
|
gptkbp:is_vulnerable_to
|
gptkb:vaccine
|
|
gptkbp:market_cap
|
$50 billion
|
|
gptkbp:operates_in
|
gptkb:China
|
|
gptkbp:parent_company
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:partnership
|
gptkb:GAVI_Alliance
gptkb:WHO
local governments
academic institutions
healthcare providers
|
|
gptkbp:product_line
|
gptkb:medical_devices
therapeutics
diagnostics
|
|
gptkbp:production_location
|
multiple locations in China
|
|
gptkbp:products
|
vaccines
|
|
gptkbp:research_and_development
|
$1 billion
|
|
gptkbp:research_focus
|
biopharmaceuticals
|
|
gptkbp:revenue
|
$10 billion
|
|
gptkbp:subsidiary
|
Sinopharm Vaccine
|
|
gptkbp:supply_chain
|
integrated
|
|
gptkbp:sustainability_initiatives
|
community health programs
environmental responsibility
employee welfare programs
|
|
gptkbp:website
|
www.sinopharm.com
|
|
gptkbp:bfsParent
|
gptkb:Nürnberg_Messe_China
|
|
gptkbp:bfsLayer
|
7
|